Avalo Therapeutics (AVTX) Acquisitions (2017 - 2024)

Avalo Therapeutics (AVTX) posted Acquisitions of $356000.0 for Q1 2024, up 35599900.0% on a QoQ basis from $1.0 in Q1 2018.

Avalo Therapeutics (AVTX) Acquisitions (2017 - 2024) Analysis & Trends

Avalo Therapeutics' Acquisitions history runs 3 years deep, the most recent figure standing at $356000.0 for Q1 2024.

Quarterly Acquisitions changed N/A year-over-year to $356000.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $356000.0 (changed N/A YoY) and the FY2024 annual result came in at $356000.0, changed N/A from the prior year.
Acquisitions was $356000.0 for Q1 2024 at Avalo Therapeutics, up from $1.0 in the prior quarter.
Across five years, Acquisitions topped out at $356000.0 in Q1 2024 and bottomed at $356000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Avalo Therapeutics	1.04 Mn	1.04 Mn	-	-

Download Data